Skip to main content

Lunate Capital Ltd

SEC CIK
0002056786
Latest filing
Jul 23, 2026

The latest 13F from Lunate Capital Ltd covers Q2 2026 (filed Jul 23, 2026): 10 long positions worth $196.0M. The top 10 holdings make up 100.0% of the portfolio, and the largest is SailPoint, Inc. (SAIL) at 22.4%. Livermore has 7 filings on Form 13F from this institution, going back to Q1 2025.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
6
Est. +$118.0M
Added
0
Reduced
0
Sold out
2
Est. −$54.2M

Top 5 holdings

Share of this quarter's portfolio value

  1. SAILSailPoint, Inc.
    22.4%$43.9MHistory
  2. BIRKBirkenstock Holding plc
    22.2%$43.5MHistory
  3. LINELineage, Inc.
    13.2%$25.9MHistory
  4. BXSLBlackstone Secured Lending Fund
    12.1%$23.7MHistory
  5. GSBDGoldman Sachs BDC, Inc.
    10.6%$20.8MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. BIRKBirkenstock Holding plc
    +$43.5MNewHistory
  2. BXSLBlackstone Secured Lending Fund
    +$23.7MNewHistory
  3. GSBDGoldman Sachs BDC, Inc.
    +$20.8MNewHistory
  4. MSDLMorgan Stanley Direct Lending Fund
    +$16.7MNewHistory
  5. OBDCBlue Owl Capital Corp
    +$13.0MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. BIRKBirkenstock Holding plc
    +22.17 pp0.0% → 22.2%History
  2. BXSLBlackstone Secured Lending Fund
    +12.11 pp0.0% → 12.1%History
  3. GSBDGoldman Sachs BDC, Inc.
    +10.60 pp0.0% → 10.6%History
  4. MSDLMorgan Stanley Direct Lending Fund
    +8.51 pp0.0% → 8.5%History
  5. OBDCBlue Owl Capital Corp
    +6.66 pp0.0% → 6.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. RVMDRevolution Medicines, Inc.
    −$53.4MSold outHistory
  2. RVMDWRevolution Medicines, Inc.
    −$805.5KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. RVMDRevolution Medicines, Inc.
    −44.36 pp44.4% → 0.0%History
  2. RVMDWRevolution Medicines, Inc.
    −0.67 pp0.7% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$196.0M
+$75.6M (+62.8%) vs. prior quarter
Positions
10
+4 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
34.3%
Q2 2026, one quarter
Average holding period
2.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2025), so positions held before then are understated.

13F filings by quarter

6 quarters, going back to Q1 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $264.3M (Q4 2025)

Q1 2025: $171.2MQ2 2025: $178.1MQ3 2025: $220.7MQ4 2025: $264.3MQ1 2026: $120.4MQ2 2026: $196.0M
Q1 2025Q2 2026
13F filings of Lunate Capital Ltd by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Jul 23, 202610$196.0MSAILBIRKLINEvs. Q1 2026SEC
Q1 2026Apr 16, 20266$120.4MRVMDSAILLINEvs. Q4 2025SEC
Q4 2025Jan 23, 20266$264.3MRVMDSAILLINEvs. Q3 2025SEC
Q3 2025Nov 20, 2025Amended6$220.7MRVMDSAILFIGRvs. Q2 2025SEC
Q2 2025Jul 17, 20256$178.1MRVMDSAILLINEvs. Q1 2025SEC
Q1 2025Apr 25, 20254$171.2MRVMDSAILLINE–SEC

13D and 13G filings

Companies where Lunate Capital Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Lunate Capital Ltd owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
LIMENeutron Holdings, Inc.13G15.30%9.82M sharesNewJul 7, 20261 filingJul 7, 2026SEC

Latest filings

1 filing on file made by Lunate Capital Ltd or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Lunate Capital Ltd
CompanyFiled (ET)FormStakeChangeEvent dateFiling
LIMENeutron Holdings, Inc.Jul 7, 202612:14 PM ET13G15.30%9.82M sharesNewJun 30, 2026SEC